Better Predictive Modelling for Better Drug Development
Discover how predictive modelling, QSP, AI, and systems biology creates better drug development by connecting biological evidence with better predictions.
Articles, expert interviews, and insights from life sciences leaders
Could Biological Ageing Be the Next Big Shift in Drug Discovery?
“The pharma industry is beginning to look at biological age as a surrogate endpoint to improve clinical trials."
Read interview: How Should Pharma Companies Audit AI Vendors?
Read interview: Could Biological Ageing Be the Next Big Shift in Drug Discovery?
Read interview: Is AI Quietly Creating a GDPR Crisis in Clinical Research?
Read interview: How AI Is Reshaping Data Integrity in Pharma Manufacturing
Read interview: AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech
Read interview: AI in Pharma: Hype vs. What Actually Works
Read interview: How Pharmacy Innovation Is Changing Healthcare Delivery
Read interview: The Role of Regulatory Leadership in Healthcare
Exclusive Pharmatica Content
Explore expert-led podcasts, pharmaceutical intelligence, life sciences insights and research-driven analysis from leading industry voices. Pharmatica delivers trusted biotech news, drug development trends and commercial intelligence for professionals across the pharmaceutical sector.
FDA Oncology Trial Guidance Targets Eligibility Barriers
FDA oncology clinical trial guidance targets restrictive eligibility criteria, covering performance status, washout periods, medications, and laboratory values.
Could q-CAR Redefine Drug Discovery?
Find out how q-CAR drug discovery moves beyond static protein structures by linking protein dynamics, ligand activity, and AI to precision drug design.
FDA Generic Peptides Guidance Sets New Expectations
Revised FDA draft guidance for generic peptide products updates expectations for ANDAs, impurities, structure, immune response, and biological activity.
Nanocarriers Target the Eye for Better Ocular Drug Delivery
Ocular drug delivery faces major biological barriers. Nanocarriers could improve bioavailability, tissue targeting, controlled release, and treatment for difficult eye diseases.
Collaborating for R&D Success in Drug Discovery
Collaboration in drug discovery can shape pharma R&D success. Explore the evidence on pharma partnerships, knowledge sharing, governance, and innovation.
AI in GMP Manufacturing: Are Regulators Ready for Digital Factories?
Learn how AI in pharmaceutical GMP manufacturing is improving quality, data integrity, predictive maintenance, and regulatory compliance in modern drug production.
Psychedelic Drug Discovery Gets a New Preclinical Framework
Find out how psychedelic drug discovery is evolving through receptor pharmacology, behavioural science, and neuroplasticity to develop safer CNS therapeutics.
Using Machine Learning for Lipid Nanoparticle Design
Read about machine learning for lipid nanoparticle design used to improve cell, gene, and RNA drug delivery and help optimise next-generation therapeutics.
Could Biological Ageing Be the Next Big Shift in Drug Discovery?
“The pharma industry is beginning to look at biological age as a surrogate endpoint to improve clinical trials."
What Drives Pharmaceutical R&D Success? New Benchmarking Reveals Why Some Drug Pipelines Outperform Others
Explore new benchmarking research on pharmaceutical R&D success rates, revealing why some drug pipelines consistently achieve higher approval rates than others.
FAST-EU Pilot: Can Europe Finally Accelerate Multinational Clinical Trials?
The FAST-EU Pilot aims to accelerate multinational clinical trials through faster coordinated assessments, supporting Europe’s 2030 clinical research ambitions.
